Hot flashes are the most recognised symptom of menopause, yet most explanations stop at "declining estrogen causes them." That is true but unhelpfully vague. The mechanism was poorly understood for decades, which limited treatment to estrogen replacement or general symptom management. It is now well characterised, and that understanding is what made it possible to develop the first targeted non-hormonal treatment specifically for hot flashes (fezolinetant, approved 2023), and what explains the therapeutic logic behind every available option.

The Thermoregulatory Null Zone

Your body maintains core temperature within a narrow range called the thermoregulatory null zone. When temperature rises above the upper boundary, you sweat; when it drops below the lower boundary, you shiver. The hypothalamus monitors and regulates this zone continuously, and in the range between those boundaries, no thermoregulatory response fires.

In premenopausal women, the null zone is roughly 0.4°C wide.[1] In women with frequent hot flashes, this zone narrows to near zero: almost any small thermal perturbation triggers a thermoregulatory response.[1] This is why mild triggers (a warm room, a hot drink, stress) are enough to set off a flush. The system's calibration is wrong, and the calibration error comes from the brain, not from the body's temperature itself.

The KNDy Neurons

The mechanism behind this miscalibration was identified through research on a cluster of neurons in the hypothalamic arcuate nucleus called KNDy neurons.[2] The name is an acronym: these cells co-express three neuropeptides: kisspeptin (K), neurokinin B (N), and dynorphin (Dy).

KNDy neurons are best known for regulating reproductive hormone secretion. They form a pulse generator that controls gonadotropin-releasing hormone (GnRH) release, which in turn drives LH and FSH secretion. They also project directly to the thermoregulatory regions of the hypothalamus, specifically the median preoptic nucleus (MnPO), which governs heat dissipation responses.[3]

Estrogen normally suppresses KNDy neuron activity, particularly neurokinin B release. When estrogen is withdrawn at menopause, that suppression is removed. The KNDy neurons become hyperactive and physically hypertrophy, releasing excess neurokinin B.[2]

The Cascade That Produces a Hot Flash

Neurokinin B binds to the neurokinin-3 receptor (NK3R) in the median preoptic nucleus. MnPO neurons expressing NK3R connect to downstream heat dissipation pathways: they trigger cutaneous vasodilation, sweating, and increased heart rate. These are the body's normal responses to overheating, now being fired by faulty neuronal signalling rather than by actual heat.[3]

The sequence in real time:

  1. KNDy neurons fire in the arcuate nucleus
  2. Neurokinin B is released and reaches the median preoptic nucleus
  3. NK3R activation in the MnPO triggers the heat dissipation programme
  4. Peripheral blood vessels dilate rapidly (the flushing and warmth sensation)
  5. Sweating begins as the body tries to cool a skin surface that is suddenly receiving more blood flow
  6. Heart rate increases to pump blood to the skin
  7. Adrenaline is released as part of the arousal response
  8. Core temperature may actually drop slightly, which is why some women feel cold after a flush

The entire event is driven from the brain. Core temperature before the flush is typically normal. The hypothalamus fires the response before any real overheating occurs.

Why Estrogen Volatility Worsens Hot Flashes

This mechanism explains why early perimenopause, characterised by erratic estrogen surges and crashes, tends to produce worse vasomotor symptoms than the more stable low-estrogen state of postmenopause. When estrogen fluctuates widely, the KNDy neurons are intermittently suppressed and then released, repeatedly recalibrating the thermoregulatory zone. Each withdrawal event triggers a bout of heightened sensitivity.

In established postmenopause with consistently low estrogen, the system reaches a new lower equilibrium. Hot flashes continue but often reduce in frequency for many women over the years following the final menstrual period.

Why the Treatments Work

Estrogen replacement restores the suppressive signal on KNDy neurons, reducing NKB release and returning the thermoregulatory null zone toward normal. This is why HRT is the most effective available treatment: it targets the mechanism at its source.

Fezolinetant (the NK3R antagonist approved in 2023) blocks neurokinin B from binding to its receptor in the median preoptic nucleus. It does not change KNDy neuron activity or circulating NKB levels, but it prevents downstream activation of heat dissipation pathways. This approach achieves roughly 56–61% reduction in hot flash frequency[4] without hormones.

SSRIs and SNRIs reduce hot flash frequency through a different pathway: modulating serotonergic and noradrenergic tone in the central nervous system, which affects thermoregulatory signalling indirectly. They are less effective than estrogen or fezolinetant but are an option for women who cannot use either, including women with hormone-sensitive cancers or those with contraindications to NK3R antagonists.

Alcohol, caffeine, stress, and warm environments narrow the thermoregulatory null zone further or add a thermal or arousal stimulus to a system already set to fire at minimal provocation. Managing these triggers does not address the underlying mechanism but can meaningfully reduce the frequency of events that cross the threshold.

When to Seek Clinical Assessment

Hot flashes that occur seven or more times per day, disrupt sleep on most nights, or persist beyond ten years after the final menstrual period warrant a conversation with a clinician. Severity thresholds like these are used in clinical trials to define candidates for pharmacological treatment, and the same benchmarks are a reasonable guide for seeking evaluation. A clinician can also rule out non-menopausal causes (hyperthyroidism, carcinoid syndrome, certain medications) that produce flushing through different mechanisms.

References

[1] Freedman, R. R., Krell, W. (1999). Reduced thermoregulatory null zone in postmenopausal women with hot flashes. American Journal of Obstetrics and Gynecology, 181(1), 66-70. https://doi.org/10.1016/S0002-9378(99)70432-4

[2] Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., Krajewski-Hall, S. J. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: A novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211-227. https://pmc.ncbi.nlm.nih.gov/articles/PMC3833827/

[3a] Mittelman-Smith, M. A., Williams, H., Krajewski-Hall, S. J., Lai, J., Ciofi, P., McMullen, N. T., Rance, N. E. (2012). Arcuate kisspeptin/NKB/dynorphin neurons mediate the estrogen suppression of gonadotropin secretion and body weight. Endocrinology, 153(6), 2800-2812.

[3b] Role for KNDy neurons in cutaneous vasodilation and estrogen modulation. https://pmc.ncbi.nlm.nih.gov/articles/PMC3511761/

[4] Fraser, G. L., et al. (2023). Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. Journal of Clinical Endocrinology & Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC10348473/